Research & Development
Hospital Acquired Infection
Sentinel creates coronavirus test, adds more PCR tests
The company's Stat-NAT COVID-19 assay is a freeze-dried, ready-to-use, real-time polymerase chain reaction (PCR) mix that can detect the presence of the SARS-CoV-2 virus, which causes COVID-19, in human respiratory tract specimens in about 90 minutes.
March 12, 2020
NeuMoDx and Sentinel partner on PCR assays
New molecular diagnostics will be developed in a range of areas, including for use in post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections. The collaborative work will incorporate Sentinel's Stat-NAT technology, which the companies said was designed to stabilize the activity of the PCR mix to boost shelf life, among other advantages.
December 9, 2019
GNA Biosolutions secures $13.5M in new funding round
GNA said it plans to use the funds to advance the development of its point-of-care molecular diagnostic platform as well as help bring it to the clinic -- first in the European Union and then in the U.S. market. The platform can support the creation of simple, cost-effective molecular diagnostic tests and has already facilitated the production of more than 30 internal assays for hospital-acquired infections and tuberculosis, among other diseases, according to the firm.
August 4, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Page 1 of 1